BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38386085)

  • 1. MET receptor serves as a promising target in melanoma brain metastases.
    Redmer T; Schumann E; Peters K; Weidemeier ME; Nowak S; Schroeder HWS; Vidal A; Radbruch H; Lehmann A; Kreuzer-Redmer S; Jürchott K; Radke J
    Acta Neuropathol; 2024 Feb; 147(1):44. PubMed ID: 38386085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
    Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
    Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of systemic therapy in melanoma brain metastases: a narrative review.
    Saleem K; Davar D
    Chin Clin Oncol; 2022 Jun; 11(3):24. PubMed ID: 35818856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
    Sloot S; Chen YA; Zhao X; Weber JL; Benedict JJ; Mulé JJ; Smalley KS; Weber JS; Zager JS; Forsyth PA; Sondak VK; Gibney GT
    Cancer; 2018 Jan; 124(2):297-305. PubMed ID: 29023643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
    Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis.
    Bonfill-Teixidor E; Iurlaro R; Handl C; Wichmann J; Arias A; Cuartas I; Emmenegger J; Romagnani A; Mangano L; Lorber T; Berrera M; Godfried Sie C; Köchl F; Eckmann J; Feddersen R; Kornacker M; Schnetzler G; Cicuendez M; Cordero E; Topczewski TE; Ferres-Pijoan A; González J; Martínez-Ricarte F; Muñoz-Couselo E; Tabernero J; Bischoff JR; Pettazzoni P; Seoane J
    Cancer Res; 2022 Jul; 82(14):2552-2564. PubMed ID: 35584009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
    Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
    Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
    Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma brain metastases: Biological basis and novel therapeutic strategies.
    Phadke M; Ozgun A; Eroglu Z; Smalley KSM
    Exp Dermatol; 2022 Jan; 31(1):31-42. PubMed ID: 33455008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice.
    Jablonska PA; Fong CH; Kruser T; Weiss J; Liu ZA; Takami H; Narita Y; Ynoe de Moraes F; Dasgupta A; Ong CK; Yang JCH; Lee JH; Pavlakis N; Kongkham P; Butler M; Shultz DB
    Radiother Oncol; 2022 Mar; 168():89-94. PubMed ID: 35121033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
    Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
    J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
    Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
    Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain Metastases.
    Pomeranz Krummel DA; Nasti TH; Izar B; Press RH; Xu M; Lowder L; Kallay L; Rupji M; Rosen H; Su J; Curran W; Olson J; Weinberg B; Schniederjan M; Neill S; Lawson D; Kowalski J; Khan MK; Sengupta S
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):157-163. PubMed ID: 32057994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
    Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
    Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF
    Jandova J; Park SL; Corenblum MJ; Madhavan L; Snell JA; Rounds L; Wondrak GT
    Mol Carcinog; 2022 Jun; 61(6):603-614. PubMed ID: 35417045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
    Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
    J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
    Niessner H; Forschner A; Klumpp B; Honegger JB; Witte M; Bornemann A; Dummer R; Adam A; Bauer J; Tabatabai G; Flaherty K; Sinnberg T; Beck D; Leiter U; Mauch C; Roesch A; Weide B; Eigentler T; Schadendorf D; Garbe C; Kulms D; Quintanilla-Martinez L; Meier F
    Cancer Med; 2013 Feb; 2(1):76-85. PubMed ID: 24133630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition.
    Alvarez-Breckenridge C; Markson SC; Stocking JH; Nayyar N; Lastrapes M; Strickland MR; Kim AE; de Sauvage M; Dahal A; Larson JM; Mora JL; Navia AW; Klein RH; Kuter BM; Gill CM; Bertalan M; Shaw B; Kaplan A; Subramanian M; Jain A; Kumar S; Danish H; White M; Shahid O; Pauken KE; Miller BC; Frederick DT; Hebert C; Shaw M; Martinez-Lage M; Frosch M; Wang N; Gerstner E; Nahed BV; Curry WT; Carter B; Cahill DP; Boland GM; Izar B; Davies MA; Sharpe AH; Suvà ML; Sullivan RJ; Brastianos PK; Carter SL
    Cancer Immunol Res; 2022 Aug; 10(8):996-1012. PubMed ID: 35706413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.